Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.43 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 7/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30339347 | 1.00 | RIPK1 (0.43) | RIPK1PANK3ACACBRETNR1H2 | |
| SCHEMBL25294807 | 0.84 | RIPK1 (0.47) | RIPK1PANK3ACACBNR1H2NR1H3 | |
| SCHEMBL30338972 | 0.82 | RIPK1 (0.43) | RIPK1PANK3ACACBNR1H2NR1H3 | |
| SCHEMBL20565724 | 0.76 | RIPK1 (0.44) | RIPK1 | |
| SCHEMBL21868480 | 0.72 | RIPK1 (0.55) | RIPK1PANK3ACACBNR1H2NR1H3 | |
| SCHEMBL22389879 | 0.70 | PANK3 (0.50) | RIPK1PANK3ACACBCHRM2CTSS | |
| SCHEMBL25262820 | 0.69 | RIPK1 (0.45) | RIPK1PANK3CHRM2CTSS | |
| SCHEMBL28671204 | 0.69 | PANK3 (0.47) | RIPK1PANK3ACACBCHRM2CTSS | |
| SCHEMBL30547508 | 0.69 | KDM4E (0.41) | PANK3ACACBCHRM2CTSS | |
| SCHEMBL25296464 | 0.66 | CRBN (0.41) | NR1H2NR1H3CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK4, RIPK2 | RIPK1 1/4885PANK3 202/4885ACACB 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.